Disabling TP53 mutations are enriched in chemotherapy-treated patients, suggesting that an inactivation of the pro-apoptotic ATM-CHK2-p53 signaling cascade is selected for in CLL (Puente et al., 2011; Quesada et al., 2011). This evidence concerns the gene CHEK2 and B-cell chronic lymphocytic leukemia.